

SAFETY DATA SHEET

Product Name: Sodium Chloride Injection, USP

1. CHEMICAL PRODUCT AND COMPANY IDENTIFICATION

Manufacturer Name And Hospira, Inc.

Address 275 North Field Drive

Lake Forest, Illinois 60045

USA

Emergency Telephone CHEMTREC: North America: 800-424-9300;

International 1-703-527-3887; Australia - 61-290372994; UK - 44-870-8200418

Hospira, Inc., Non-Emergency 224 212-2000

Product Name Sodium Chloride Injection, USP

Synonyms Table salt

2. HAZARD(S) IDENTIFICATION

Emergency Overview Sodium Chloride Injection, USP is a solution containing sodium chloride. In clinical

use, sodium chloride is used in the management of deficiencies of sodium and chloride ions in salt-losing conditions. In the workplace, concentrated sodium chloride solutions may be irritating to the eyes and respiratory tract. Based on clinical use, possible target organs may include the cardiovascular system, gastrointestinal system

and nervous system.

U.S. OSHA GHS Classification

Physical Hazards Hazard Class Hazard Category

Not Classified Not Classified

Health Hazards Hazard Class Hazard Category

Eye Damage / Irritation 2A

Label Element(s)

•

 $\langle ! \rangle$

Signal Word Warning

Hazard Statement(s) Causes serious eye irritation

Precautionary Statement(s)

Pictogram

Prevention Do not breathe vapor or spray

Wash hands thoroughly after handling Wear eye protection/face protection

Response Get medical attention if you feel unwell.

IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. If eye irritation persists, get medical

attention.

Product Name: Sodium Chloride Injection, USP



3. COMPOSITION/INFORMATION ON INGREDIENTS

Active Ingredient Name Sodium Chloride

Chemical Formula NaCl

Component	Approximate Percent by Weight	CAS Number	RTECS Number
Sodium Chloride	1 to 24	7647-14-5	VZ4725000

Non-hazardous ingredients include Water for Injection. Hazardous ingredients present at less than 1% may include hydrochloric acid which is added to adjust the pH.

4. FIRST AID MEASURES

Eye Contact Remove from source of exposure. Flush with copious amounts of water. If

irritation persists or signs of toxicity occur, seek medical attention. Provide

symptomatic/supportive care as necessary.

Skin Contact Remove from source of exposure. Flush with copious amounts of water. If

irritation persists or signs of toxicity occur, seek medical attention. Provide

symptomatic/supportive care as necessary.

Inhalation Remove from source of exposure. If signs of toxicity occur, seek medical attention.

Provide symptomatic/supportive care as necessary.

Ingestion Remove from source of exposure. If signs of toxicity occur, seek medical attention.

Provide symptomatic/supportive care as necessary

5. FIRE FIGHTING MEASURES

Flammability None anticipated for this aqueous product.

Fire & Explosion HazardNone anticipated for this aqueous product.

Extinguishing Media As with any fire, use extinguishing media appropriate for primary cause of fire such

as carbon dioxide, dry chemical extinguishing powder or foam.

Special Fire Fighting Procedures No special provisions required beyond normal firefighting equipment such as flame

and chemical resistant clothing and self contained breathing apparatus.

6. ACCIDENTAL RELEASE MEASURES

Spill Cleanup and Disposal Isolate area around spill. Put on suitable protective clothing and equipment as

specified by site spill control procedures. Absorb the liquid with suitable material and clean affected area with soap and water. Dispose of spill materials according to

the applicable federal, state, or local regulations.

7. HANDLING AND STORAGE

Handling No special handling required under conditions of normal product use.

Storage No special storage required for hazard control. For product protection, follow

storage recommendations noted on the product case label, the primary container

label, or the product insert.

Special Precautions No special precautions required for hazard control.



8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Exposure Guidelines

		Exposure Limits			
Component	OSHA-PEL	ACGIH-TLV	AIHA WEEL	Hospira EEL	
Sodium Chloride	8-hr TWA: Not	8-hr TWA: Not	8-hr TWA: Not	8-hr TWA: Not	
	Established	Established	Established	Established	

Notes: OSHA PEL: US Occupational Safety and Health Administration - Permissible Exposure Limit

ACGIH TLV: American Conference of Governmental Industrial Hygienists - Threshold Limit Value.

AIHA WEEL: Workplace Environmental Exposure Level

EEL: Employee Exposure Limit. TWA: 8-hour Time Weighted Average.

Respiratory Protection Respiratory protection is normally not needed during intended product use.

> However, if the generation of aerosols is likely, and engineering controls are not considered adequate to control potential airborne exposures, the use of an approved air-purifying respirator with a HEPA cartridge (N95 or equivalent) is recommended under conditions where airborne aerosol concentrations are not expected to be excessive. For uncontrolled release events, or if exposure levels are not known, provide respirators that offer a high protection factor such as a powered air purifying respirator or supplied air. A respiratory protection program that meets OSHA's 29 CFR 1910.134 and ANSI Z88.2 requirements must be followed whenever workplace conditions require respirator use. Personnel who wear respirators should be fit

tested and approved for respirator use as required.

If skin contact with the product formulation is likely, the use of latex or nitrile **Skin Protection**

gloves is recommended.

Eye protection is normally not required during intended product use. However, if **Eye Protection**

eye contact is likely to occur, the use of chemical safety goggles (as a minimum) is

recommended.

Engineering Controls Engineering controls are normally not needed during the normal use of this product.

9. PHYSICAL/CHEMICAL PROPERTIES

Appearance/Physical State A sterile, non-pyrogenic, concentrated solution

Odor NA **Odor Threshold** NA

5.0 (4.5 to 7.0) pΗ

Melting point/Freezing Point NA **Initial Boiling Point/Boiling Point Range** NA **Flash Point** NA **Evaporation Rate** NA Flammability (solid, gas) NA **Upper/Lower Flammability or Explosive Limits** NA Vapor Pressure NA NA

Solubility Freely soluble in water; practically insoluble in dehydrated alcohol

NA

Partition Coefficient: n-octanol/water NA **Auto-ignition Temperature** NA **Decomposition Temperature** NA Viscosity NA

Vapor Density (Air =1)

Relative Density

Product Name: Sodium Chloride Injection, USP



10. STABILITY AND REACTIVITY

Not determined. None anticipated from this product. Reactivity

Stable under standard use and storage conditions. **Chemical Stability**

Not determined **Hazardous Reactions** Not determined Conditions to Avoid **Incompatibilities** Not determined

Hazardous Decomposition

Products irritating vapors and/or toxic fumes of hydrogen chloride and sodium oxide.

Not determined. During thermal decomposition, it may be possible to generate

Hazardous Polymerization Not anticipated to occur with this product.

11. TOXICOLOGICAL INFORMATION

Acute Toxicity - Not determined for the product formulation. Information for the active ingredient is as follows:

Ingredient(s)	Percent	Test Type	Route of Administration	Value	Units	Species
Sodium Chloride	100	LD50	Oral	3000	mg/kg	Rat
Sodium Chloride	100	LD50	Oral	4000	mg/kg	Mouse
Sodium Chloride	100	LD50	Dermal	> 10,000	mg/kg	Rabbit
Sodium Chloride	100	LC50(1hr)	Inhalation	> 42,000	mg/m3	Rat
Sodium Chloride	100	LD50	Intraperitoneal	2600 2602	mg/kg mg/kg	Rat Mouse
Sodium Chloride	100	LD50	Intravenous	645	mg/kg	Mouse

LD 50: Dosage that produces 50% mortality.

Occupational Exposure Potential

Information on the absorption of this product via inhalation or skin contact is not available. Avoid liquid aerosol generation and skin contact.

Signs and Symptoms

None anticipated from normal handling of this product. In the workplace, this product should be considered potentially irritating to the eyes and respiratory tract. In clinical use, gastrointestinal effects associated with acute oral ingestion of excessive amounts of sodium chloride include nausea, vomiting, diarrhea, and abdominal cramps. Excessive use of chloride salts may cause a loss of bicarbonate with an acidifying effect. Retention of excess sodium and accumulation of excess water may also occur and may lead to pulmonary and peripheral edema. Hypernatremia has rarely occurred with the use of saline for induction of emesis or for gastric lavage. However, hypernatremia may occur after inappropriate intravenous use of hypertonic saline. The most serious effect of hypernatremia is dehydration of the brain which causes somnolence and confusion progressing to convulsions, coma, respiratory failure, and death. Other symptoms include thirst, reduced salivation and lachrymation, fever, sweating, tachycardia, hypertension or hypotension, headache, dizziness, restlessness, irritability, weakness, and muscular twitching and rigidity.

Aspiration Hazard None anticipated from normal handling of this product.

Dermal Irritation/ Corrosion None anticipated from normal handling of this product. In animal studies, sodium

chloride was reported to be a mild skin irritant. However, inadvertent contact of this

product with skin is not anticipated to produce irritation.

None anticipated from normal handling of this product. In animal studies, sodium **Ocular Irritation/ Corrosion**

chloride was reported to be a mild to moderate irritant. Inadvertent contact of this

product with eyes may produce irritation with redness and discomfort.



11. TOXICOLOGICAL INFORMATION: continued

Dermal or Respiratory

Sensitization None anticipated from normal handling of this product.

Reproductive EffectsNone anticipated from normal handling of this product. Physiological sodium

chloride solutions are often used as negative controls in teratology experiments and

do not appear to produce adverse effects on embryological development.

Administration of sodium chloride has been reported not to be teratogenic in rats, hamsters, and pigs. Subcutaneous injection of 1900 or 2500 mg sodium chloride in pregnant mice increased the incidence of minor skeletal anomalies in the offspring. Increased neonatal body weight was reported in offspring of rats fed high (8%) salt

diets when compared to the offspring of dams fed low salt diets.

Mutagenicity Sodium chloride was negative in the Ames test, with and without metabolic

activation. Sodium chloride was positive for genotoxicity in an in vitro mouse

lymphoma assay.

NA

Carcinogenicity The carcinogenic potential of sodium chloride has not been fully evaluated.

Carcinogen Lists IARC: Not listed NTP: Not listed OSHA: Not listed

Specific Target Organ Toxicity –

Single Exposure

Specific Target Organ Toxicity -

Repeat Exposure

Based on clinical use, possible target organs may include the cardiovascular system,

gastrointestinal system and nervous system.

12. ECOLOGICAL INFORMATION

Aquatic Toxicity Not determined for product. Information for sodium chloride is as follows:

LC50(96hr, flow through) = 9675-11,100 mg/L in freshwater fish LC50(96hr, static) = 7341-17,550 mg/L in freshwater fish

LC50(24hr, static) = 7341-17,550 mg/L in freshwater fish LC50(24hr, static) = 13,750 - 14,125 mg/L in freshwater fish

LC50(48 hr) = 3310 mg/L in Daphnia magna.

Persistence/Biodegradability Not determined for product.

Bioaccumulation Not determined for product.

Mobility in Soil Not determined for product.

Notes:

1. EC50: Concentration in water that produces 50% mortality in Daphnia sp.

2. LC50: Concentration in water that produces 50% mortality in fish.

3. EC50: Concentration in water that produces 50% inhibition of growth in algae.

13. DISPOSAL CONSIDERATIONS

Waste Disposal All waste materials must be properly characterized. Further, disposal should be

performed in accordance with the federal, state or local regulatory requirements.

Container Handling and

Disposal

Dispose of container and unused contents in accordance with federal, state and local

regulations.



14. TRANSPORTATION INFORMATION

ADR/ADG/ DOT STATUS Not regulated

Proper Shipping Name NA
Hazard Class NA
UN Number NA
Packing Group NA
Reportable Quantity NA

ICAO/IATA STATUS Not regulated

Proper Shipping Name NA
Hazard Class NA
UN Number NA
Packing Group NA
Reportable Quantity NA

IMDG STATUS Not regulated

Proper Shipping Name
NA
Hazard Class
NA
UN Number
NA
Packing Group
NA
Reportable Quantity
NA

Notes: DOT - US Department of Transportation Regulations

15. REGULATORY INFORMATION

US TSCA Status Exempt. However, sodium chloride is listed on the TSCA inventory.

US CERCLA Status
US SARA 302 Status
US SARA 313 Status
US RCRA Status
US PROP 65 (Calif.)
Not listed
Not listed
Not listed

Notes: TSCA, Toxic Substance Control Act; CERCLA, US EPA law, Comprehensive Environmental Response, Compensation, and Liability Act; SARA, Superfund Amendments and Reauthorization Act; RCRA, US EPA, Resource Conservation and Recovery Act; Prop 65, California Proposition 65

GHS/CLP Classification*

*In the EU, classification under GHS/CLP does not apply to certain substances and mixtures, such as medicinal products as defined in Directive 2001/83/EC, which are in the finished state, intended for the final user.

Hazard Class	Hazard Category	Pictogram	Signal Word	Hazard Statement
NA	NA	NA	NA	NA
Prevention	Do not breathe vapor or Wash hands thoroughly Wear eye protection/fac	after handling		

Response Get medical attention if you feel unwell.

IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. If eye irritation persists, get medical

attention.

EU Classification* *Medicinal products are exempt from the requirements of the EU Dangerous

Preparations Directive.

Classification(s) NA
Symbol NA
Indication of Danger NA
Risk Phrases NA

Safety Phrases S23: Do not breathe vapor/spray

S24: Avoid contact with the skin S25: Avoid contact with eyes

S37/39 Wear suitable gloves and eye/face protection.



16. OTHER INFORMATION

Notes:

ACGIH TLV American Conference of Governmental Industrial Hygienists – Threshold Limit Value

CAS Chemical Abstracts Service Number

CERCLA US EPA law, Comprehensive Environmental Response, Compensation, and Liability Act

DOT US Department of Transportation Regulations

EEL Employee Exposure Limit

IATA International Air Transport Association LD₅₀ Dosage producing 50% mortality NA Not applicable/Not available

NE Not established

NIOSH National Institute for Occupational Safety and Health

OSHA PEL US Occupational Safety and Health Administration – Permissible Exposure Limit

Prop 65 California Proposition 65

RCRA US EPA, Resource Conservation and Recovery Act
RTECS Registry of Toxic Effects of Chemical Substances
SARA Superfund Amendments and Reauthorization Act

STEL 15-minute Short Term Exposure Limit

STOT - SE Specific Target Organ Toxicity – Single Exposure STOT - RE Specific Target Organ Toxicity – Repeated Exposure

TSCA Toxic Substance Control Act
TWA 8-hour Time Weighted Average

MSDS Coordinator: Hospira GEHS
Date Prepared: October 19, 2012
Date Revised: June 02, 2014

Disclaimer:

The information and recommendations contained herein are based upon tests believed to be reliable. However, Hospira does not guarantee their accuracy or completeness NOR SHALL ANY OF THIS INFORMATION CONSTITUTE A WARRANTY, WHETHER EXPRESSED OR IMPLIED, AS TO THE SAFETY OF THE GOODS, THE MERCHANTABILITY OF THE GOODS, OR THE FITNESS OF THE GOODS FOR A PARTICULAR PURPOSE. Adjustment to conform to actual conditions of usage may be required. Hospira assumes no responsibility for results obtained or for incidental or consequential damages, including lost profits, arising from the use of these data. No warranty against infringement of any patent, copyright or trademark is made or implied.